Find a Clinical Trial

Showing 61 - 70 of 169 Trials

  • A phase 2 study of fixed therapy with pirtobrutinib and obinutuzumab in previously untreated chronic lymphocytic leukemia (POP)

    Principal Investigator:

    Andrew H Lipsky, MD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT06333262

    Population:

    Adult

    Phase:

    II
    The purpose of this study is to learn about possible initial treatments for chronic lymphocytic leukemia (CLL). This study will evaluate the investigational drug pirtobrutinib in combination with the commercially available drug obinutuzumab to treat CLL. The U.S. Food and Drug Administration (FDA) has approved pirtobrutinib for the treatment of CLL that has returned (relapsed) or is resistant to other treatments. Pirtobrutinib i is not FDA approved for the first-time treatment of CLL. The FDA has approved obinutuzumab for the Are you Eligible? (Inclusion Criteria) Must be ≥18 years of age...

  • A Phase 2 Randomized, Multicenter Study to Evaluate the Efficacy and Safety of Silevertinib, an Oral EGFR Inhibitor, in Combination with Temozolomide in Patients with Newly Diagnosed Glioblastoma with Unmethylated MGMT Promoter and EGFRvIII

    Principal Investigator:

    Peter Chei-Way Pan, MD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT07326566

    Population:

    Adult

    Phase:

    II
    The purpose of this study is to see if combining silevertinib with temozolomide after surgery and radiotherapy helps treat cancer better than using temozolomide alone. Silevertinib has not been approved by the Food and Drug Administration (FDA). Temozolomide is FDA approved but not in combination with silevertinib. Are you Eligible? (Inclusion Criteria) Must be 18 years old or older - Cannot have major surgery within 4 weeks before first dose of study drug or scheduled for surgery during the study - Cannot have poorly controlled gastrointestinal disorders that may interfere with absorption of...

  • A Phase 2 Multicenter Study of TL-895 in Subjects withMyelofibrosis, Indolent Systemic Mastocytosis, MonoclonalMast Cell Activation Syndrome, or Non-Monoclonal Mast CellActivation Syndrome

    Principal Investigator:

    Joseph G. Jurcic, MD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT04655118

    Population:

    Adult

    Phase:

    II
    The purpose of this study is to evaluate whether the investigational drug TL-895, which has not been approved by the U.S. Food and Drug Administration (FDA), can help improve symptoms in people with indolent systemic mastocytosis (ISM). TL-895 is being studied alone, in combination with avapritinib, and in comparison with either placebo or avapritinib. Avapritinib is an approved drug that is already used to treat certain types of systemic mastocytosis. A placebo is a treatment with no active therapeutic effect, used to compare against an investigational drug. The main goals of the study are...

  • Cascade Testing In Racially/Ethnically Diverse Relatives of Patients with Breast or Ovarian Cancer (CASSIE)

    Principal Investigator:

    Alissa Michel, MD

    Contact Number:

    212-342-5162

    Population:

    Adult

    Phase:

    II
    The study is being done to answer the following question: How can we best help women with family members who have cancer and a genetic mutation in a cancer gene make decisions about undergoing genetic testing? We are doing this study because we want to better understand if our web-based tool, RealRisks, can help women with family members who have a genetic variant make an informed decision about genetic testing. Are you Eligible? (Inclusion Criteria) 18 years or older. - Both men and women of all races and ethnic groups are eligible as probands for this trial. Only female first-degree...

  • Chemo4METPANC - A Phase 2 study with combination Chemotherapy (Gemcitabine and Nab-Paclitaxel), chemokine (C-X-C) motif receptor 4 inhibitor (Motixafortide), and immune checkpoint blockade (Cemiplimab) in METastatic treatment naïve PANCreas

    Principal Investigator:

    Gulam A. Manji, MD, PhD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT04543071

    Population:

    Adult

    Phase:

    II
    You are being invited to take part in this research study because you have been diagnosed with pancreas cancer that has spread to other parts of the body. The purpose of this study is to determine if combination treatment with cemiplimab, motixafortide, gemcitabine, and nab-paclitaxel is effective in decreasing tumor size and prolonging life in patients with advanced pancreas cancer. The treatment consists of both immunotherapy (cemiplimab and motixafortide) and chemotherapy (gemcitabine and nab-paclitaxel). Gemcitabine and nab-paclitaxel are approved by the Food and Drug Administration (FDA...

  • Defining the role of ctDNA monitoring in a novel, risk stratified clinical trial for PTLD.

    Principal Investigator:

    Jennifer Effie Amengual, MD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT06954805

    Population:

    Pediatrics/Adult

    Phase:

    II
    The purpose of this study is to find out if there is a benefit to giving rituximab with etoposide, prednisone, vincristine, cyclophosphamide and doxorubicin (R-EPOCH) in patients who have high-risk Bcell posttransplant lymphoproliferative disorder (PTLD), while those with low-risk disease will be spared of chemotherapy and treated with rituximab alone. Concurrently this study also wants to see how helpful a new blood test called circulating tumor DNA (ctDNA) is. This test has already helped doctors make better predictions and treatment decisions in other types of lymphoma. The goal is to...

  • EXACT: Randomized phase II trial of XL092 in combination with immunotherapy in patients who progress on Adjuvant therapy in Clear Cell RCC

    Principal Investigator:

    Karie Danielle Keera Runcie, MD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT06863311

    Population:

    Adult

    Phase:

    II
    The purpose of this study is to see if study drug XL092 alone or in combination with nivolumab can treat your cancer after your cancer has progressed on adjuvant treatment. Researchers also want to look at the safety of the XL092 alone and in combination with nivolumab. We are asking you to take part in this research study because you have clear cell renal cell carcinoma (clear cell kidney cancer), and your disease has come back after adjuvant treatment (treatment given after your disease progresses from your first treatment). - XL092 is not approved by the U.S. Food and Drug Administration (...

  • Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging and Molecular Analysis 2

    Principal Investigator:

    Meghna S Trivedi, MD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT01042379

    Population:

    Adult

    Phase:

    II
    The primary purpose of this trial is to determine whether adding new drugs to the standard initial cancer treatments for breast cancer increases the probability there there will be no residual disease (cancer cells left after many attempts to remove the cancer), compared to the initial cancer treatment alone. The intervention includes different drugs to determine which study drugs might result in better outcomes than standard treatment. Are you Eligible? (Inclusion Criteria) To be eligible for this trial patients must: have breast cancer and cannot already have had chemotherapy. be at least...

  • MOMENTUM-1: A Multicenter, Randomized, Open-Label, Phase II Study of [177LU]LU-DOTATATE in Adults With Progressive Intracranial Grade 1-3 Meningioma

    Principal Investigator:

    Mary R. Welch, MD, MS

    Contact Number:

    212-342-5162

    NCT Number:

    NCT06955169

    Population:

    Adult

    Phase:

    II
    The purpose of this study is to find out if the study drug, [177Lu]Lu-DOTATATE, is better or worse than the usual drug therapy in treating meningioma that has come back after treatment with surgery, radiation, and/or drug therapy. [177Lu]Lu-DOTATATE is a radioactive drug, called a radiopharmaceutical, that works by targeting only the tumor and then delivering radiation into the tumor. [177Lu]Lu-DOTATATE has already been approved by the Food and Drug Administration (FDA) to treat other types of tumors, but it has not been approved to treat meningiomas. Are you Eligible? (Inclusion Criteria)...

  • MRD-GUIDED SEQUENTIAL THERAPY FOR DEEP RESPONSE IN NEWLY DIAGNOSED MULTIPLE MYELOMA - MASTER-2 TRIAL

    Principal Investigator:

    Rajshekhar Chakraborty, MD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT05231629

    Population:

    Adult

    Phase:

    II
    The purpose of the study is to determine the proportion of patients with lowest minimal residual disease (MRD) response obtainable after receiving 6 cycles of study treatment. Minimal residual disease is multiple myeloma cells below the level of 1 cancer cell out of 100,000 in the bone marrow. For patients who are MRD “positive” at the end of 6 cycles of therapy, this study will answer whether more patients can become and remain MRD “negative” with autologous hematopoietic cell transplantation (AHCT) plus a new immunotherapy called teclistamab in combination with...

Pages

Back to top